These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36295829)

  • 21. Association of alkaptonuria and low dose nitisinone therapy with cataract formation in a large cohort of patients.
    Ahmad MSZ; Ahmed M; Khedr M; Borgia A; Madden A; Ranganath LR; Kaye S
    JIMD Rep; 2022 Jul; 63(4):351-360. PubMed ID: 35822094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and biochemical assessment of depressive symptoms in patients with Alkaptonuria before and after two years of treatment with nitisinone.
    Davison AS; Harrold JA; Hughes G; Norman BP; Devine J; Usher J; Hughes AT; Khedr M; Gallagher JA; Milan AM; J C G H; Ranganath LR
    Mol Genet Metab; 2018 Sep; 125(1-2):135-143. PubMed ID: 30049652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of low dose nitisinone in the management of alkaptonuria.
    Sloboda N; Wiedemann A; Merten M; Alqahtani A; Jeannesson E; Blum A; Henn-Ménétré S; Guéant JL; Renard E; Feillet F
    Mol Genet Metab; 2019 Jul; 127(3):184-190. PubMed ID: 31235217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing the effect of nitisinone induced hypertyrosinaemia on monoamine neurotransmitters in brain tissue from a murine model of alkaptonuria using mass spectrometry imaging.
    Davison AS; Strittmatter N; Sutherland H; Hughes AT; Hughes J; Bou-Gharios G; Milan AM; Goodwin RJA; Ranganath LR; Gallagher JA
    Metabolomics; 2019 Apr; 15(5):68. PubMed ID: 31037385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nitisinone causes acquired tyrosinosis in alkaptonuria.
    Khedr M; Cooper MS; Hughes AT; Milan AM; Davison AS; Norman BP; Sutherland H; Jarvis JC; Fitzgerald R; Markinson L; Psarelli EE; Ghane P; Deutz NEP; Gallagher JA; Ranganath LR
    J Inherit Metab Dis; 2020 Sep; 43(5):1014-1023. PubMed ID: 32083330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria Centre.
    Ranganath LR; Khedr M; Milan AM; Davison AS; Hughes AT; Usher JL; Taylor S; Loftus N; Daroszewska A; West E; Jones A; Briggs M; Fisher M; McCormick M; Judd S; Vinjamuri S; Griffin R; Psarelli EE; Cox TF; Sireau N; Dillon JP; Devine JM; Hughes G; Harrold J; Barton GJ; Jarvis JC; Gallagher JA
    Mol Genet Metab; 2018 Sep; 125(1-2):127-134. PubMed ID: 30055994
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urine homogentisic acid and tyrosine: simultaneous analysis by liquid chromatography tandem mass spectrometry.
    Hughes AT; Milan AM; Christensen P; Ross G; Davison AS; Gallagher JA; Dutton JJ; Ranganath LR
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jul; 963():106-12. PubMed ID: 24952314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of a protein-restricted diet on body weight and serum tyrosine concentrations in patients with alkaptonuria.
    Olsson B; Ranganath L; Arnoux JB; Imrich R; Milan A; Rudebeck M
    JIMD Rep; 2022 Jan; 63(1):41-49. PubMed ID: 35028270
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Joint replacement risk is markedly increased in alkaptonuria (AKU) in those with prior arthroplasty.
    Ranganath LR; Khedr M; Norman BP; Hughes JH; Imrich R; Arnoux JB; Olsson B; Rudebeck M; Gallagher JA; Bou-Gharios G
    Mol Genet Metab Rep; 2024 Sep; 40():101097. PubMed ID: 38846518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Homogentisic acid is not only eliminated by glomerular filtration and tubular secretion but also produced in the kidney in alkaptonuria.
    Ranganath LR; Milan AM; Hughes AT; Khedr M; Davison AS; Shweihdi E; Norman BP; Hughes JH; Bygott H; Luangrath E; Fitzgerald R; Psarelli EE; van Kan C; Laan D; Olsson B; Rudebeck M; Mankowitz L; Sireau N; Arnoux JB; Le Quan Sang KH; Jarvis JC; Genovese F; Braconi D; Santucci A; Zatkova A; Glasova H; Stančík R; Imrich R; Rhodes NP; Gallagher JA
    J Inherit Metab Dis; 2020 Jul; 43(4):737-747. PubMed ID: 31609457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic Effects of Increasing Doses of Nitisinone in the Treatment of Alkaptonuria.
    Gertsman I; Barshop BA; Panyard-Davis J; Gangoiti JA; Nyhan WL
    JIMD Rep; 2015; 24():13-20. PubMed ID: 25665838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum markers in alkaptonuria: simultaneous analysis of homogentisic acid, tyrosine and nitisinone by liquid chromatography tandem mass spectrometry.
    Hughes AT; Milan AM; Davison AS; Christensen P; Ross G; Gallagher JA; Dutton JJ; Ranganath LR
    Ann Clin Biochem; 2015 Sep; 52(Pt 5):597-605. PubMed ID: 25628464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluating the aortic stenosis phenotype before and after the effect of homogentisic acid lowering therapy: Analysis of a large cohort of eighty-one alkaptonuria patients.
    Ranganath LR; Heseltine T; Khedr M; Fisher MF
    Mol Genet Metab; 2021 Jul; 133(3):324-331. PubMed ID: 34059444
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interferences of homogentisic acid (HGA) on routine clinical chemistry assays in serum and urine and the implications for biochemical monitoring of patients with alkaptonuria.
    Curtis SL; Roberts NB; Ranganath LR
    Clin Biochem; 2014 May; 47(7-8):640-7. PubMed ID: 24373924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone.
    Preston AJ; Keenan CM; Sutherland H; Wilson PJ; Wlodarski B; Taylor AM; Williams DP; Ranganath LR; Gallagher JA; Jarvis JC
    Ann Rheum Dis; 2014 Jan; 73(1):284-9. PubMed ID: 23511227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nitisinone Arrests but Does Not Reverse Ochronosis in Alkaptonuric Mice.
    Keenan CM; Preston AJ; Sutherland H; Wilson PJ; Psarelli EE; Cox TF; Ranganath LR; Jarvis JC; Gallagher JA
    JIMD Rep; 2015; 24():45-50. PubMed ID: 25940034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased prevalence of Parkinson's disease in alkaptonuria.
    Ranganath L; Khedr M; Milan AM; Davison AS; Norman BP; Janssen MCH; Lock E; Bou-Gharios G; Gallagher JA
    JIMD Rep; 2023 Jul; 64(4):282-292. PubMed ID: 37404676
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reversal of ochronotic pigmentation in alkaptonuria following nitisinone therapy: Analysis of data from the United Kingdom National Alkaptonuria Centre.
    Ranganath LR; Milan AM; Hughes AT; Khedr M; Davison AS; Wilson PJ; Dillon JP; West E; Gallagher JA
    JIMD Rep; 2020 Sep; 55(1):75-87. PubMed ID: 32904992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adequacy of nitisinone for the management of alkaptonuria.
    Abbas K; Basit J; Rehman MEU
    Ann Med Surg (Lond); 2022 Aug; 80():104340. PubMed ID: 36045846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of nitisinone in patients with alkaptonuria.
    Suwannarat P; O'Brien K; Perry MB; Sebring N; Bernardini I; Kaiser-Kupfer MI; Rubin BI; Tsilou E; Gerber LH; Gahl WA
    Metabolism; 2005 Jun; 54(6):719-28. PubMed ID: 15931605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.